• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma.

作者信息

Jung Sung-Hoon, Lee Je-Jung, Song Ga-Young, Lee Ho Sup, Kim Seok Jin, Yoon Sang Eun, Kim Kihyun

机构信息

Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Jeollanamdo, Republic of Korea.

Kosin University Gospel Hospital, Busan, Republic of Korea.

出版信息

Br J Haematol. 2022 Feb;196(4):1117-1120. doi: 10.1111/bjh.17898. Epub 2021 Oct 20.

DOI:10.1111/bjh.17898
PMID:34671972
Abstract
摘要

相似文献

1
Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma.参与临床试验通过增加多发性骨髓瘤新治疗药物的可及性来改善生存结局。
Br J Haematol. 2022 Feb;196(4):1117-1120. doi: 10.1111/bjh.17898. Epub 2021 Oct 20.
2
Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial.对于泊马度胺和地塞米松治疗反应不足时加用环磷酰胺：II期PERSPECTIVE多发性骨髓瘤试验结果
Blood Cancer J. 2019 Apr 8;9(4):45. doi: 10.1038/s41408-019-0206-8.
3
Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.卡非佐米、来那度胺与低剂量地塞米松用于老年新诊断多发性骨髓瘤患者的治疗
Haematologica. 2014 Sep;99(9):e162-4. doi: 10.3324/haematol.2014.110395. Epub 2014 Jun 27.
4
Bortezomib in multiple myeloma.硼替佐米用于治疗多发性骨髓瘤。
N Engl J Med. 2005 Sep 22;353(12):1297-8; author reply 1297-8.
5
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.达雷妥尤单抗、来那度胺和地塞米松与来那度胺和地塞米松单独治疗新诊断多发性骨髓瘤（MAIA）的疗效比较：一项随机、开放标签、3 期临床试验的总生存结果。
Lancet Oncol. 2021 Nov;22(11):1582-1596. doi: 10.1016/S1470-2045(21)00466-6. Epub 2021 Oct 13.
6
Advances in the treatment of elderly patients with multiple myeloma.
Clin Adv Hematol Oncol. 2006 Jul;4(7):501-2.
7
Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice.在常规临床实践中，来那度胺和地塞米松（Rd）与伊沙佐米、来那度胺和地塞米松（IRD）相比，对复发和难治性多发性骨髓瘤患者的生存获益。
BMC Cancer. 2021 Jan 15;21(1):73. doi: 10.1186/s12885-020-07732-1.
8
Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma.在FIRST试验中，肾功能损害对来那度胺和地塞米松治疗结局的影响，这是一项针对不符合移植条件的多发性骨髓瘤患者的随机、开放标签3期试验。
Haematologica. 2016 Mar;101(3):363-70. doi: 10.3324/haematol.2015.133629. Epub 2015 Dec 11.
9
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.硼替佐米联合来那度胺及地塞米松每周给药方案用于首次复发或原发性难治性骨髓瘤的I/II期试验
Haematologica. 2016 Apr;101(4):e149-52. doi: 10.3324/haematol.2015.132431. Epub 2015 Dec 11.
10
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.

引用本文的文献

1
Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings.学术及社区医疗环境中的多发性骨髓瘤护理、治疗模式及治疗持续时间。
Future Oncol. 2025 Jun;21(15):1905-1918. doi: 10.1080/14796694.2025.2504318. Epub 2025 May 21.
2
Scoping Review of Barriers and Facilitators to Recruitment of Black People With Cancer in Biospecimen-Based Research.基于生物样本研究招募癌症黑人患者的障碍和促进因素的范围综述。
JCO Precis Oncol. 2024 May;8:e2300708. doi: 10.1200/PO.23.00708.
3
Outcomes of Patients with Newly Diagnosed Transplant-Ineligible Multiple Myeloma According to Clinical Trials Enrollment: Experience of a Single Institution.
根据临床试验入组情况分析新诊断的不适合移植的多发性骨髓瘤患者的预后：单中心经验
Cancers (Basel). 2023 Nov 2;15(21):5261. doi: 10.3390/cancers15215261.